BeyondSpring Inc. (BYSI)
| Market Cap | 25.50M -66.0% |
| Revenue (ttm) | n/a |
| Net Income | -6.69M |
| EPS | -0.16 |
| Shares Out | 41.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,310 |
| Open | 0.6200 |
| Previous Close | 0.6202 |
| Day's Range | 0.6051 - 0.6300 |
| 52-Week Range | 0.5657 - 2.4400 |
| Beta | 0.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropen... [Read more]
Financial Performance
Financial StatementsNews
BeyondSpring Proxy statement: Proxy filing
BeyondSpring filed a proxy statement on September 3, 2026, providing details for shareholder voting and corporate governance matters.
BeyondSpring Proxy statement: Proxy filing
BeyondSpring filed a proxy statement on September 3, 2026, providing details for shareholder voting and corporate governance matters.
BeyondSpring Slides: Investor presentation
BeyondSpring has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2026.
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy
BeyondSpring Quarterly report: Q2 2026
BeyondSpring has published its Q2 2026 quarterly earnings report on August 14, 2026.
BeyondSpring Earnings release: Q2 2026
BeyondSpring released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
BeyondSpring Slides: Corporate presentation
BeyondSpring has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
BeyondSpring appoints Min Qiu as CEO, Na Li as CFO
BeyondSpring (BYSI) announced a leadership transition. The leadership changes become effective July 1. The board has appointed Min Qiu as CEO of BeyondSpring, effective July 1. Qiu has been actively…
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class therapies...
BeyondSpring announces updated data from 303 Study
BeyondSpring (BYSI) announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients with metastatic non-...
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment...
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment ...
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Mol...
BeyondSpring Earnings release: Q1 2026
BeyondSpring released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
BeyondSpring Quarterly report: Q1 2026
BeyondSpring has published its Q1 2026 quarterly earnings report on May 13, 2026.
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy
BeyondSpring Slides: Corporate presentation
BeyondSpring has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
BeyondSpring Files 2025 Annual Report on Form 10-K
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatmen...
BeyondSpring Annual report: Q4 2025
BeyondSpring has published its Q4 2025 annual report on March 25, 2026.
BeyondSpring Earnings release: Q4 2025
BeyondSpring released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...
BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress
BeyondSpring (BYSI) announced results from the Asian subset of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-typ...
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC
BeyondSpring (BYSI) announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study showing that Plinabulin plus docetaxel provides clinically meaningful benefit for patients with EGFR wild-typ...
BeyondSpring reports Q3 EPS (4c) vs (5c) last year
“With over 700 patients treated, Plinabulin continues to demonstrate a favorable safety profile and meaningful potential as an immune-modulating therapy with unique mechanism of dendritic cell (DC) ma...